Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial).
Breyer J, Eckstein M, Sikic D, Wezel F, Roghmann F, Brehmer M, Wirtz RM, Jarczyk J, Erben P, Bahlinger V, Goldschmidt F, Fechner G, Chen J, Paxinos E, Bates M, Haas M, Zengerling F, Bolenz C, Burger M, Hartmann A, Kriegmair MC; BRIDGE Consortium e.V.. Breyer J, et al. Among authors: jarczyk j. Sci Rep. 2023 Sep 18;13(1):15437. doi: 10.1038/s41598-023-42088-z. Sci Rep. 2023. PMID: 37723173 Free PMC article.
Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert® BC Monitor.
Haas M, Kriegmair MC, Breyer J, Sikic D, Wezel F, Roghmann F, Brehmer M, Wirtz RM, Jarczyk J, Erben P, Bahlinger V, Goldschmidt F, Fechner G, Chen J, Paxinos E, Bates M, Zengerling F, Bolenz C, Burger M, Hartmann A, Eckstein M. Haas M, et al. Among authors: jarczyk j. BJU Int. 2024 May 8. doi: 10.1111/bju.16389. Online ahead of print. BJU Int. 2024. PMID: 38717014
PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma.
Klümper N, Wüst L, Saal J, Ralser DJ, Zarbl R, Jarczyk J, Breyer J, Sikic D, Wullich B, Bolenz C, Roghmann F, Hölzel M, Ritter M, Strieth S, Hartmann A, Erben P, Wirtz RM, Landsberg J, Dietrich D, Eckstein M. Klümper N, et al. Among authors: jarczyk j. Oncoimmunology. 2023 Oct 19;12(1):2267744. doi: 10.1080/2162402X.2023.2267744. eCollection 2023. Oncoimmunology. 2023. PMID: 37868689 Free PMC article.
Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy.
Neuberger M, Weiß C, Goly N, Skladny J, Nitschke K, Wessels F, Kowalewski KF, Waldbillig F, Hartung F, Nientiedt M, Egen L, Herrmann J, Jarczyk J, Walach MT, Kriegmair MC, Westhoff N, Worst TS, Nuhn P. Neuberger M, et al. Among authors: jarczyk j. Discov Oncol. 2022 Dec 15;13(1):140. doi: 10.1007/s12672-022-00603-0. Discov Oncol. 2022. PMID: 36522513 Free PMC article.
Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort.
Neuberger M, Goly N, Skladny J, Milczynski V, Weiß C, Wessels F, Nitschke K, Grüne B, Haney CM, Hartung F, Herrmann J, Jarczyk J, Kowalewski KF, Waldbillig F, Kriegmair MC, Westhoff N, Worst TS, Nuhn P. Neuberger M, et al. Among authors: jarczyk j. J Cancer Res Clin Oncol. 2023 Jul;149(7):3371-3381. doi: 10.1007/s00432-022-04220-w. Epub 2022 Aug 8. J Cancer Res Clin Oncol. 2023. PMID: 35939112 Free PMC article.
C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.
Klümper N, Sikic D, Saal J, Büttner T, Goldschmidt F, Jarczyk J, Becker P, Zeuschner P, Weinke M, Kalogirou C, Breyer J, Burger M, Nuhn P, Tully K, Roghmann F, Bolenz C, Zengerling F, Wirtz RM, Muders M, Kristiansen G, Bald T, Ellinger J, Wullich B, Hölzel M, Hartmann A, Erben P, Ritter M, Eckstein M. Klümper N, et al. Among authors: jarczyk j. Eur J Cancer. 2022 May;167:13-22. doi: 10.1016/j.ejca.2022.02.022. Epub 2022 Mar 30. Eur J Cancer. 2022. PMID: 35366569 Free article.
Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hormone-sensitive Prostate Cancer Treated With Docetaxel Chemotherapy.
Neuberger M, Skladny J, Goly N, Wessels F, WEIß C, Egen L, Erben P, GROß-Weege M, Grüne B, Hartung F, Herrmann J, Honeck P, Jarczyk J, Kowalewski KF, Mühlbauer J, Nitschke K, Nientiedt M, Walach MT, Waldbillig F, Westhoff N, VON Hardenberg J, Kriegmair M, Worst TS, Nuhn P. Neuberger M, et al. Among authors: jarczyk j. Anticancer Res. 2022 Apr;42(4):1911-1918. doi: 10.21873/anticanres.15668. Anticancer Res. 2022. PMID: 35347010
25 results